Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Cash: 2012-2025

Historic Change in Cash for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to -$346.8 million.

  • Ptc Therapeutics' Change in Cash fell 169.33% to -$346.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.5 million, marking a year-over-year decrease of 59.12%. This contributed to the annual value of $185.0 million for FY2024, which is 41.14% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Change in Cash stood at -$346.8 million, which was up 25.07% from -$462.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Change in Cash registered a high of $700.5 million during Q1 2025, and its lowest value of -$462.8 million during Q2 2025.
  • Moreover, its 3-year median value for Change in Cash was -$43.1 million (2023), whereas its average is $35.5 million.
  • In the last 5 years, Ptc Therapeutics' Change in Cash skyrocketed by 175,514.00% in 2022 and then plummeted by 545.34% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Change in Cash stood at -$100,000 in 2021, then surged by 175,514.00% to $175.4 million in 2022, then soared by 144.49% to $428.9 million in 2023, then tumbled by 40.42% to $255.5 million in 2024, then plummeted by 169.33% to -$346.8 million in 2025.
  • Its Change in Cash was -$346.8 million in Q3 2025, compared to -$462.8 million in Q2 2025 and $700.5 million in Q1 2025.